Back to search results
NCT06735924

Influence of Metabolic Syndrome on Endogenous Oxalate Synthesis

Active, Not Recruiting
NAAges 18+InterventionalBasic science
University of Alabama at Birmingham
~28 participants
Updated 2026-05-29 on ClinicalTrials.gov
What's tested:Low-oxalate fixed diet

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
estimated endogenous oxalate synthesis rate
Measured over 1 day

Conditions

MASLD
Metabolic Dysfunction-Associated Steatotic Liver Disease

Explore related trials

Nonalcoholic Fatty Liver Disease

NCT06735924

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • University of Alabama at Birmingham

    Birmingham, Alabamano site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Kyle D Wood, MD · PRINCIPAL_INVESTIGATOR · University of Alabama at Birmingham

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

age \>18 years
History of MASLD, with liver fat content \> 5%
Normal kidney function
Stable medication for at least 1 month for diabetes mellitus if any
Willingess to ingest fixed diets and stop dietary supplements for the study and come to UAB for visits

Exclusion

Age \< 18 years
Inaccurate 24-hour urine collections
Liver fat content \<5%
Liver cirrhosis
Evidence of other chronic liver disease, viral hepatitis
history of alcoholism within 2 years of enrollment
Contra-indication to Magnetic Resonance Imaging
Chronic kidney disease with estimated Glomerular Filtration rate \< 60 ml/min/1.73m2
Type 1 Diabetes Mellitus or treatment with insulin
Uncontrolled diabetes
Pregnancy, lactation or intention to be
Uncontrolled hypertension
Use of weight loss medication, SGLT2 inhibitors, GLP-1 receptor agonists, osteoporosis medication, chronic NSAID
History of gastric or intestinal surgery or resection that could potentially alter oxalate absorption
Chronic fat malabsorption
Use of immunosuppressive medications
Known immuno-compromised status
Active malignancy or treatment for malignanacy within the last 12 months

What this trial measures

  • estimated endogenous oxalate synthesis rate1 day

    Average fasted hourly urinary oxalate excretion rate normalized to urinary creatinine excretion (mg oxalate / g urinary creatinine)